Nasreen S, Jiang Y, Lu H, Lee A, Cutland CL, Gentile A, Giglio N, Macartney K, Deng L, Liu B, Sonneveld N, Bellamy K, Clothier HJ, Kattan GS, Naus M, Naveed Z, Janjua NZ, Nguyen L, Hviid A, Poukka E, Perälä J, Leino T, Chandra LA, Thobari JA, Park BJ, Choi NK, Jeong NY, Madhi SA, Villalobos F, Solórzano M, Bissacco CA, Carreras-Martínez JJ, Correcher-Martínez E, Urchueguía-Fornes A, Roy D, Yeomans A, Aurelius T, Morton K, Di Mauro G, Sturkenboom MC, Sejvar JJ, Top KA, Batty K, Ghebreab L, Griffin JB, Petousis-Harris H, Buttery J, Black S, Kwong JC Full text Adverse events COVID-19 Surveillance 2025 Vaccine 2025;60:127291. doi: 10.1016/j.vaccine.2025.127291